

Dkt. #696-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : N. Rosen et al.
U.S. Serial No. : 09/445,054 Examiner: Rebecca Cook
Filed : March 27, 2000 Group Art Unit: 1614
For : A METHOD OF TREATING CANCER

Law Offices of Albert Wai-Kit Chan, LLC
World Plaza, Suite 604
141-07 20th Avenue
Whitestone, NY 11357

September 14, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir/Madam:

AMENDMENT IN RESPONSE TO THE SEPTEMBER 8, 2004 TELEPHONE
INTERVIEW WITH THE EXAMINER TO PLACE THIS APPLICATION
IN CONDITION FOR ALLOWANCE

This Amendment is being submitted in response to the September 8, 2004 telephone interview with the Examiner in connection with the above-identified application to place the Application in condition for allowance.

There is no deadline for filing this Amendment. Accordingly, this Amendment is being timely filed.

Applicants : M. Rosen et al.
U.S. Serial No. : 09/445,054
Filing Date : March 27, 2000
Page : 2

In the Claims:

Please cancel claims 49, 50, 51, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62 and 63-69 without prejudice to the Applicants' right to submit the canceled claims in a continuation application, and add new claims 70-83.

1 - 69. (Canceled)

Please add the following proposed new claims 70-83:

70. (New) A method for achieving a synergistic therapeutic effect in a mammal in need thereof which comprises administering to said mammal amounts of at least two therapeutic agents selected from a group consisting of:

- a) a prenyl-protein transferase inhibitor and
- b) an antineoplastic agent selected from paclitaxel, epothilone A, epothilone B, desoxyepothilone A or desoxyepothilone B,

wherein the synergistic therapeutic effect is the treatment of cancers of the brain, breast, colon, genitourinary tract, lymphatic system, pancreas, rectum, stomach, larynx, liver, lung, prostate, stet histiocytic lymphoma lung adenocarcinoma, pancreatic carcinoma, colo-rectal carcinoma, small cell lung cancers or neurological tumor cancer whose growth is inhibited by the administration of the prenyl-protein transferase inhibitor and the antineoplastic agent.

71. (New) The method according to Claim 70 wherein the prenyl-protein transferase inhibitor is selected from:

2(S)-Butyl-1-(2,3-diaminoprop-1-yl)-1-(1-naphthoyl)piperazine;

1-(3-Amino-2-(2-naphthylmethylamino)prop-1-yl)-2(S)-butyl-4-(1-naphthoyl)piperazine;

2(S)-Butyl-1-(5-[1-(2-naphthylmethyl)]-4,5-dihydroimidazol)methyl-4-(1-naphthoyl)piperazine;